HS patients are likely to experience “flare-ups” of symptoms regardless of their treatment modality and discontinuing any of these medications would result in a relatively quick relapse of disease symptoms. Only ~60% of HS patients using adalimumab (anti-TNF therapy) have clinical responses without adverse effects, and only 50% of infliximab (anti-TNF therapy) users experience reductions in lesion size and/or severity. However, ustekinumab (anti-TNF therapy) achieved symptom improvement rates as high as 82%. This evidence concerns the gene TNF and histiocytic sarcoma.